文献速递神经核医学肿瘤 PET/CT

11C-乙酸盐PET/CT在预测脑胶质瘤肿瘤分化与生存中的作用

The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-03-06

前瞻性纳入73例经手术证实的脑胶质瘤患者(19例II级、21例III级、33例IV级),术前行11C-乙酸盐PET/CT,比较不同WHO分级组的肿瘤与脉络丛摄取比(TCR),并计算代谢肿瘤体积(MTV)。结果显示TCR在三组间有显著差异(P<0.001),TCR和MTV为独立预后因素,预测生存优于WHO分级。

要点

  • TCR在WHO II、III、IV级胶质瘤中位数分别为1.20、1.65、2.53,三组间差异显著(P<0.001)。
  • Cox回归显示TCR为PFS预后因素(P=0.016),TCR和MTV为OS预后因素(P=0.024、P=0.030)。
  • TCR≥1.6者PFS和OS显著短于TCR<1.6者。

核心结论

  • 11C-乙酸盐PET/CT的TCR在低级别与高级别脑胶质瘤间显著不同,并能进一步区分III级与IV级肿瘤。
  • TCR和MTV是独立预后因素,预测生存优于WHO分级。

研究设计与样本

  • 前瞻性研究纳入73例经手术证实的脑胶质瘤患者(19例II级、21例III级、33例IV级),术前接受11C-乙酸盐PET/CT检查。
  • 比较三组WHO分级间的TCR(肿瘤最大SUV与脉络丛平均SUV之比),并计算MTV。
  • 采用Kaplan-Meier法绘制PFS和OS曲线,log-rank检验比较组间生存差异,Cox回归分析预后因素。

主要发现

  • TCR中位数在II级为1.20(IQR 1.14–1.4),III级为1.65(IQR 1.26–1.79),IV级为2.53(IQR 1.93–3.30),三组间差异显著(P<0.001)。
  • Cox回归分析(纳入TCR、MTV、分子标志物及其他临床因素)显示,TCR为PFS的预后因素(P=0.016);TCR和MTV为OS的预后因素(P=0.024和P=0.030)。
  • TCR≥1.6的患者PFS和OS显著短于TCR<1.6者。
  • MTV≥1的患者OS显著短于TCR<1者(原文此处写作TCR<1,按上下文应为MTV<1)。

关键数值与推荐

  • TCR定义为肿瘤最大SUV与脉络丛平均SUV之比。
  • TCR≥1.6与TCR<1.6分组比较PFS和OS。
  • MTV≥1与MTV<1分组比较OS(原文写作TCR<1,按上下文应为MTV<1)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This prospective study aimed to evaluate the clinical values of 11C-acetate positron emission tomography/computed tomography (PET/CT) in predicting histologic grades and survival in patients with cerebral glioma. METHODS: Seventy-three patients with surgically confirmed cerebral gliomas (19 grade II, 21 grade III, and 33 grade IV) who underwent 11C-acetate PET/CT before surgery were included. Tumor-to-choroid plexus ratio (TCR), which was defined as the maximum standardized uptake value (SUV) of tumors to the mean SUV of choroid plexus, was compared between three World Health Organization (WHO) grade groups. Moreover, metabolic tumor volumes (MTV) were calculated. Progression-free survival (PFS) and overall survival (OS) curves were plotted using the Kaplan-Meier method, and differences in survival between groups were assessed using the log-rank test. RESULTS: Median TCR was 1.20 (interquartile range [IQR], 1.14 to 1.4) in grade II, 1.65 (IQR, 1.26 to 1.79) in grade III, and 2.53 (IQR, 1.93 to 3.30) in grade IV gliomas. Significant differences in TCR were seen among the three WHO grade groups (P < 0.001). In Cox regression analysis including TCR, MTV, molecular markers, and other clinical factors, TCR was prognostic for PFS (P = 0.016) and TCR and MTV were prognostic for OS (P = 0.024 [TCR], P = 0.030 [MTV]). PFS and OS were significantly shorter in patients with a TCR ≥ 1.6 than in those with a TCR < 1.6. OS were significantly shorter in patients with a MTV ≥ 1 than in those with a TCR < 1. CONCLUSIONS: TCR on 11C-acetate PET/CT significantly differed between low- and high-grade cerebral gliomas, and it showed the capability to further differentiate grade III from grade IV tumors. TCR and MTV were independent prognostic factors and predicted survival better than did the WHO grade.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kim S, Kim D, Kim SH, et al. The roles of 11C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma. Eur J Nucl Med Mol Imaging. 2018. PMID: 29511838. doi:10.1007/s00259-018-3948-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。